Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 11/20 | 0.43 |
| ▸ | GPR4 | P46093 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21850937 | 0.81 | CXCR4 (0.40) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL14307263 | 0.79 | CXCR4 (0.53) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL24135318 | 0.76 | KCNJ1 (0.43) | CXCR4GPR4MEN1CHRM2CHRM1 | |
| SCHEMBL21850793 | 0.76 | KCNJ1 (0.45) | CXCR4GPR4MEN1CHRM2CHRM1 | |
| SCHEMBL16622427 | 0.75 | CXCR4 (0.51) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL20168136 | 0.75 | EGLN2 (0.46) | HRH3KCNJ1 | |
| SCHEMBL30751809 | 0.75 | EGLN2 (0.46) | HRH3KCNJ1 | |
| Hydrochloric Acid SCHEMBL16612149 | 0.74 | CXCR4 (0.53) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL20037919 | 0.74 | CXCR4 (0.62) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL21850898 | 0.72 | EGLN1 (0.45) | KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | CXCR4 666/4885GPR4 688/4885MEN1 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.